These findings are important considerations for drug discovery efforts based on this model because they suggest that the vasculature can recover when tau levels are reduced, suggesting that late stage interventions targeting tau may be useful for slowing the vascular contributions to cognitive impairment and dementia that occur in tauopathies. The gene discussed is MAPT; the disease is dementia.